MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- GLAXOSMITHKLINE PHARMACEUTICALS LTD. (pharmaceuticals)
- Latest 8 Quarter Result
GSK Pharma Quarterly Results (GLXO)
Here are the latest quarterly results of GSK Pharma. For more details, see the GSK Pharma financial fact sheet and GSK Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
GSK Pharma Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
3
Dec-19 |
3
Mar-20 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,357 | 8,163 | 8,254 | 7,512 | 7,880 | 8,821 | 7,787 | 7,759 | |
| Other income | Rs m | 178 | 148 | 164 | 525 | 305 | 156 | 163 | 152 | |
| Turnover | Rs m | 7,534 | 8,311 | 8,418 | 8,037 | 8,186 | 8,977 | 7,949 | 7,910 | |
| Expenses | Rs m | 5,953 | 6,512 | 6,880 | 5,876 | 6,225 | 6,879 | 6,540 | 6,018 | |
| Gross profit | Rs m | 1,321 | 1,534 | 1,655 | 1,605 | 1,655 | 5,954 | -6,123 | 1,854 | |
| Depreciation | Rs m | 114 | 115 | 120 | 137 | 191 | 227 | 183 | 226 | |
| Interest | Rs m | 2 | 2 | 1 | 1 | 9 | 9 | 30 | 15 | |
| Profit before tax | Rs m | 1,383 | 1,565 | 1,698 | 1,992 | 1,760 | 5,874 | -6,173 | 1,764 | |
| Tax | Rs m | 497 | 557 | 568 | 761 | 626 | 846 | 268 | 385 | |
| Profit after tax | Rs m | 886 | 1,008 | 1,130 | 1,230 | 1,135 | 5,028 | -6,441 | 1,379 | |
| Gross profit margin | % | 18.0 | 18.8 | 20.0 | 21.4 | 21.0 | 67.5 | -78.6 | 23.9 | |
| Effective tax rate | % | 35.9 | 35.6 | 33.5 | 38.2 | 35.5 | 14.4 | -4.3 | 21.8 | |
| Net profit margin | % | 12.0 | 12.3 | 13.7 | 16.4 | 14.4 | 57.0 | -82.7 | 17.8 | |
| Diluted EPS | Rs | 5.2 | 5.9 | 6.7 | 7.3 | 6.7 | 29.7 | -38.0 | 8.1 | |
| Diluted EPS (TTM) | Rs | 24.4 | 22.7 | 24.1 | 25.1 | 26.6 | 50.3 | 5.6 | 6.5 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: GSK Pharma 2QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: NATCO PHARMA INDRAPRASTHA MEDICAL DISHMAN PHARMA PIRAMAL ENTERPRISES INDOCO REMEDIES
Compare GSK PHARMA With: NATCO PHARMA INDRAPRASTHA MEDICAL DISHMAN PHARMA PIRAMAL ENTERPRISES INDOCO REMEDIES
Compare GSK PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends Flat; Telecom and Healthcare Stocks Witness Selling(Closing)
Indian share markets erased the opening gains and ended marginally lower for the second consecutive day today.
Views on news
GSK PHARMA Share Price Up by 5%; BSE HEALTHCARE Index Down 0.6% (Market Updates)
Aug 13, 2020 | Updated on Aug 13, 2020GSK PHARMA share price is trading up by 5% and its current market price is Rs 1,540. The BSE HEALTHCARE is down by 0.6%. The top gainers in the BSE HEALTHCARE Index are GSK PHARMA (up 5.2%) and CAPLIN POINT (up 8.2%). The top losers are GRANULES INDIA and ASTRAZENECA PHARMA (down 0.1%).
GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)
Oct 25, 2019 | Updated on Oct 25, 2019For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)
Jul 24, 2019 | Updated on Jul 24, 2019For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsMost Popular
Large Opportunities Are Coming Our Way
Aug 5, 2020Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.
Is It Time to Book Profits in Gold and Silver? (Fast Profits Daily)
Aug 10, 2020Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?
Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks (Profit Hunter)
Aug 6, 2020Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.
This 20 Year Cycle Suggests Gold is Set for an August Rally (Profit Hunter)
Jul 31, 2020The real reason why gold prices will go up more.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2020
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
GSK PHARMA SHARE PRICE
Aug 13, 2020 (Close)
TRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA 5-YR ANALYSIS
COMPARE GSK PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.